Elon Musk’s space agency SpaceX is already in the midst of planning its upcoming space missions but is still fairly new in the space exploration scene. As the firm continues its rocket testing, Russia’s space agency ROCOSMOS took a little swipe at Musk’s firm, saying that it cannot compare to its achievements.
The head of ROCOSMOS, Dmitry Rogozin, weighed in on the recent tests being done by SpaceX in preparation for their upcoming missions. Noting that Musk’s agency does its testing at its base at Boca Chica, South Texas, Rogozin took a swipe at the privately-owned firm. The ROCOSMOS head took to Facebook to say that SpaceX will not be able to do what ROCOSMOS does.
“This is not Boca Chica. This is Yakutia, and in winter,” said Rogozin. “The 2 OneWeb 42 mission security management calculation was deployed two days before yesterday’s launch. Temperature - minus 52C. Temperature restrictions on launches for the Union-2 - minus 40 degrees. Yesterday it was about 30 degrees - not serious. I wonder if gentle SpaceX is able to work with such conditions? But I don’t care about Russians. We are used to frost…”
However, there are users that pointed out in response to Rogozin that SpaceX reuses its rockets, ROCOSMOS does not. This is the latest swipe taken by Rogozin at the US-based agency. Back in 2014, Rogozin said that the US may as well transport its astronauts to the International Space Station with the use of a trampoline, noting how the US has had to rely on the Russian agency since 2011 to transport its astronauts to the ISS.
Previously, SpaceX’s last mission of the year was deemed a great success in sending a satellite into orbit. The mission was originally scheduled to take place on Thursday, December 17, but had to be postponed for two days due to unfavorable weather conditions. By December 19, the weather was good for launching at the Kennedy Space Center. The mission is known as NROL-108, where a confidential satellite was transported to orbit with the Falcon 9 rocket. A little after liftoff, the rocket’s booster separated when it approached near-orbit, the satellite continuing on its journey.


Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Neuralink Expands Brain Implant Trials with 12 Global Patients
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 



